Investors

Because the market for this solution is wide open, the assumption made is 30% market capture at maturity 5 years post regulatory approval.

The target market for this device is the United States due to the high rate of the main contributing pathophysiology to the disease that necessitates the device: obesity.

The team will seek an Investigational Device Exemption from the FDA before clinical trials and before being approved as a Class III device.